Ocuphire Pharma Inc
Research Ocuphire Pharma Inc (IRD) on Bullrun: market cap USD 330.47M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIRD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 330.47M
- Financial periodFY2025
- RevenueUSD 14.20M
- Revenue growth29.1%
- Net income-USD 49.59M
Valuation Snapshot
latest market cap is USD 330.47M.
About Ocuphire Pharma Inc
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Frequently asked questions
What is Ocuphire Pharma Inc's market cap?
Ocuphire Pharma Inc's market capitalization is USD 330.47M.
What does Ocuphire Pharma Inc do?
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.